00723nam0-22002771i-450-99000397351040332120071128162129.0000397351FED01000397351(Aleph)000397351FED0100039735120031015d1982----km-y0itay50------baitaScritti sceltiG. SupinoBolognaPitagora1982XXXV, 865 p.25 cmBibl. Ing. SanitariaIDRAULICASupino,Giulio<1898-1978>1963ITUNINARICAUNIMARCBK99000397351040332115 L/4-37DINIDDINIDScritti scelti473409UNINA04942nam 2201345z- 450 991055766640332120220111(CKB)5400000000044842(oapen)https://directory.doabooks.org/handle/20.500.12854/76871(oapen)doab76871(EXLCZ)99540000000004484220202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierDrug-Drug InteractionsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (242 p.)3-0365-2035-X 3-0365-2036-8 Drug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb-drug or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.Biology, life sciencesbicsscResearch & information: generalbicssc(‒)-sophoranone1A22B62C192C82C92D63A4ADMEadverse drug reactionsbiflavonoidchronic kidney diseasecompetitive inhibitioncomputational predictionCYPCYP1A1CYP1A2CYP2C9CYP2D6CYP3ACYP3A4cytochrome P450cytochromes P450DDIDexamethasonedrug interactiondrug interactionsdrug metabolismdrug transporterdrug-drug interactiondrug-drug interactiondrug-drug interactionsdrug-drug interactionsexpressionfexofenadinegepantshigh plasma protein bindingin silicoin vitroin vivoinhibitorixazomibKetoconazolelasmiditanLexicomplow permeabilityLoxoprofenmechanism-based inhibitionmetabolic DDImetabolismmigrainemonoclonal antibodiesnon-competitive inhibitionO-desmethyltramadolOATP1B1OATP1B3organic anion transporting polypeptide 1A2 (OATP1A2)P-glycoprotein (P-gp)P450pharmacokineticsphysiologically-based pharmacokineticsplasma concentrationpolypharmacypotent inhibitionQSARregulationRumex acetosaselamariscina Asignal detection algorithmsspontaneous reporting systemssubset analysissubstratesystemic exposuretadalafilticagrelortissue-specifictramadoltyrosine kinase inhibitorsubiquitinationuridine 5'-diphosphoglucuronosyl transferaseBiology, life sciencesResearch & information: generalKim Dong Hyunedt1304704Lee SangkyuedtKim Dong HyunothLee SangkyuothBOOK9910557666403321Drug-Drug Interactions3027633UNINA